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Abstract The concept of polymeric nanoparticles for the design of new drug delivery systems emerged a few
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for diagnosis and therapy of various diseases. Recent progress has made possible the engineering of
nanoparticles to allow the site-specific delivery of drugs and to improve the pharmacokinetic profile
of numerous compounds with biomedical applications such as peptide and protein drugs.
Biologically active peptides and their analogues are becoming an increasingly important class of
drugs. Their use for human and animal treatment is problematic, however, because some of these
drugs are generally ineffective when taken orally and thus have been administered chiefly by the
parenteral route. This review covers some of the historical and recent advances of nanotechnology
and concludes that polymeric nanoparticles show great promise as a tool for the development of
peptide drug delivery systems.D 2006 Elsevier Inc. All rights reserved.Key words: Biomedical applications; Nanoparticles; Peptides; ProteinsPeptide drugs are attracting increasing interest with better
understanding of their role in physiopathology, as well as
progress in biotechnology and biochemical synthesis.
However, the use of peptides and proteins in medicine has
been limited by low bioavailability, which results from their
poor stability to proteolytic and hydrolytic degradation, low
permeability across barriers, and short biologic half-life in
the circulatory system [1]. Most therapeutic peptides are still
being administered by the parenteral route because of
insufficient absorption from the gastrointestinal tract (GIT).
Because of their versatility for formulation, sustained-
release properties, subcellular size, and biocompatibility
with tissues and cells, nanoparticles seem to be a promising
solution for peptide and protein administration. Much
research has been devoted to their use in the treatment ofnt matter D 2006 Elsevier Inc. All rights reserved.
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n.neufeld@chee.queensu.ca (R.J. Neufeld).or vaccination against several diseases, because they offer
several advantages over conventional dosage routes. The
literature has emphasized the importance of size and
revealed the advantages of nanoparticles over microparticles
[2]. It has been observed that a greater number of
nanoparticles crosses the epithelium than do microparticles.
Nanoparticles have received more attention than have
liposomes because of their therapeutic potential and greater
stability in biologic fluids as well as during storage [3].
Their small particle size makes colloidal preparations well
suited for parenteral administration and also possibly useful
as sustained-release injections for delivery to a specific
organ or target site. Targeting the drug to the desired site of
action would not only improve the therapeutic efficiency but
also permit a reduction in the amount of drug that must be
administered to achieve a therapeutic response, thus
minimizing unwanted toxic effects. To target the drug to a
specific cell, recent advances in nanotechnology involve the
addition of ligands to the nanoparticle surface such as
through adsorption of monoclonal antibodies or other
compounds such as transferrin, lectin, or avidin [4].iology, and Medicine 2 (2006) 53–65
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nanotechnology and the current status of peptide delivery
systems. It also describes a variety of barriers to the
absorption of orally administered peptides and predicts
new strategies to achieve the main objective—to improve
the bioavailability of peptide and protein drugs administered
by several routes, especially the oral.General absorption considerations
In comparison with other possible routes of administra-
tion, oral peptide drug delivery has many advantages. Not
only is it noninvasive and relatively free from complications
arising from the need for sterile techniques that usually
occurs with parenteral formulations, but it is also convenient
and is easily dosed with low preparation costs, all of which
should encourage patient compliance.
Considerations associated with developing effective oral
formulations (see Figure 1) for peptides are generally
attributed to susceptibility to degradation by luminal
secreted, luminal membrane-bound, and cytosolic enzymes.
Proteolysis generally starts in the stomach by a family of
aspartic proteases called pepsins, which are mostly active at
pH 2 to 3 and become inactive at a pH greater than 5. Pepsin
is normally responsible for 10% to 20% of total protein
degradation. Upon reaching the duodenum, mixtures of
peptides resulting from partial protein digestion in the
stomach are acted upon by pancreatic proteases, consisting
of the serine endopeptidase trypsin, a-chymotrypsin, elas-
tase, and exopeptidases carboxypeptidases A and B [5].
As shown in Figure 2, peptidases associated with the
intestinal mucosa are mainly located in three subcellular
fractions of the enterocytes: the surface of the brush border
membrane, the intraluminal, and the intracellular fractions
(cytoplasm and lysosomes) [6].
Proteases in the brush border and cytosol of the enterocyte
are potentially the most important barrier to the absorption of
small, biologically active peptides across the intestinal
mucosa [5]. In addition to the membrane-bound proteases,
trypsin, chymotrypsin, and other pancreatic proteases may be
adsorbed from the luminal fluid into the brush border of the
enterocyte, assisting in proteolysis of oligopeptides and
proteins [5]. Those peptides whose N-terminal amino acid
residues possess a lipophilic side chain are preferred sub-
strates for the brush border enzymes. Brush border proteases
as a group tend to prefer tri- and tetrapeptides, although they
also readily hydrolyze peptides in the range of 2 to 10 amino
acids. Specifically, about 60% of the cellular proteolytic
activity against tripeptides and 90% of the activity against
tetrapeptides can be found in the brush border.
In contrast, the general cytosolic proteases have a
preference to smaller di- and tripeptides with slight activity
against tetrapeptides. The soluble enzymes of the cytoplasm
consist mainly of dipeptidases, an aminotripeptidase, and
proline dipeptidase and prolidase, which serve to complete
the intracellular hydrolysis of di- and tripeptides that areactively transported across the brush border membrane by a
proton-dependent carrier mechanism [7].
Intracellular peptide and protein degradation may also
take place after endocytosis and uptake into the lysosomes.
Proteolytic degradation in the lysosomes is essentially
catalyzed by cathepsins and may involve exopeptidase as
well as endopeptidase activities [8].
Unlike other drug compounds, peptides and proteins are
susceptible to degradation at many anatomic locations. As
well, a given peptide or protein usually is susceptible to
degradation at more than one linkage within the molecule [5].
Another concern is the metabolic activity of microflora in
the lower small and large intestine, especially with respect to
colonic peptide delivery strategies. Colonic microflora are
composed of more than 500 species consisting of 1011 to
1012 bacteria per gram of gut content, and are capable of
several metabolic reactions, such as deglucuronidation,
decarboxylation, reduction of double bonds, ester and amide
hydrolysis, and dehydroxylation [9].
The types of enzymes encountered, the many locations
for these enzymes in the body, and the multiplicity of
potential sites of degradation on the molecule suggest that
there will be an upper limit to the percentage of an applied
dose of peptide or protein that reaches the target site.
Another difficulty with developing effective oral for-
mulations for peptide and protein drugs involves the poor
intrinsic permeability of peptides and proteins across
biologic membranes, which usually prevents passive trans-
port as a result of large molecular size, charge, and protein
hydrophilicity [10].
The tendency of peptides and proteins to be larger than
many biologically active molecules, ranging from less than
0.6 to greater than 10 kDa in a nonaggregated state, limits
their uptake through aqueous pores in the gut wall. In the
human intestine pore permeability for small molecules, ions,
and water is highest in the jejunum, intermediate in the
ileum, and lowest in the colon [5]. The pore diameter of the
mucosa (with a range from 8 to 16 2) can be considered an
important consideration in the transport of peptide mole-
cules [11]. Compounds with molecular sizes greater than
these dimensions will thus be excluded. The pore diameter
of the mucosa has been found to be modified by absorption
enhancers such as calcium chelators, fatty acids, or
surfactants [12]. An additional consideration for transport
is the charge carried by the molecule. Because negatively
charged groups predominate around the intestinal pores,
neutral or cationic compounds should pass more easily
through these paracellular aqueous pores than do anionic
compounds. Amino acids and proteins also have exceptional
acid-base properties. The 20 standard a-amino acids have at
least two acid-base groups. The pKa values of the carboxylic
groups lie in a small range around 2.2, so that above pH 3.5
these groups are entirely in their carboxylate form. All
a-amino acids have pKa values near 9.4 and are almost
completely in the ammonium ion form below pH 8.0. Of the
20 standard amino acids, 5 have charged side chains. The
Fig 1. Schematic flowchart illustrating the issues to be addressed when developing oral peptide and protein drug delivery systems. Adapted from Dorkoosh
et al. [125].
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positively charged at physiologic pH, whereas aspartic and
glutamic acids are negatively charged above pH 3. In the
physiologic pH range both the carboxylic acid and amino
groups of peptides and amino acids are entirely ionized,
resulting in a zwitterionic molecule. Therefore, peptides and
proteins will tend to be more hydrophilic than many other
biologically active molecules. This characteristic would
most likely preclude the absorption of peptides and proteins
by transcellular diffusion unless the charges were neutral-
ized through ion pairing [5]. With few exceptions, peptides
tend to be relatively insoluble in lipids and thus are
confronted by a thermodynamic barrier even when the
concentration gradient across the absorptive membrane is
favorable. Clearly, neither size and charge nor subsequent
hydrophilic character favors the transit of larger peptides
and proteins across the mucosal membrane [5].
Another difficulty with particulate oral formulations of
peptide and protein drugs is their high water solubility. Most
processes for nanoencapsulation are based on the affinity of
the compound for the lipophilic phase of an emulsion or for
the polymer. As a result, drug loading is usually less then
10%, especially with the solvent evaporation process [13].
Chemical instability of peptides and proteins is another
barrier to particulate formulation of peptides, including their
tendency to aggregate and/or adsorb to a variety of physical
and biologic surfaces [10]. Peptides and proteins often
possess physical properties that present significant formu-lation problems not encountered with many small organic
drug molecules. Because of the complex nature of peptides,
self-aggregation is always a concern in the formulation.
Other factors such as sensitivity of the peptide and proteins
to light, heat, moisture, pH, intermolecular interactions
following co-precipitation or gelling, adsorption and inter-
action with excipients are parameters which should be
investigated in order to succeed in producing a stable
association of peptides with nanoparticulate systems [13].
Many peptides and proteins are susceptible to presys-
temic metabolism with rapid postabsorptive clearance not
limited to hepatic extraction. They may remain susceptible
to degradation at other sites within the body (for example,
kidneys and blood) and while crossing the vascular endo-
thelia to the site of action [5]. Significant intestinal epithelial
cell enzymatic activity is the first postabsorptive barrier to
achieving therapeutic systemic levels. Unlike many tradi-
tional drug candidates, peptides are also highly susceptible to
enzymatic degradation in the circulating blood [14]. Opso-
nization by blood cells must also be considered, but this
review’s focus is on nanoencapsulation and its applications
to peptidic drugs, so we will not address further the subject
of postabsorptive metabolism and peptide clearance.
A significant obstacle to orally administered peptidic
nanoparticles is the intestinal diffusion barrier, because of
particular physical and chemical characteristics. To be
absorbed a specific peptide must cross the barrier, which
comprises an unstirred water layer, mucus layer, apical and
Fig 2. Sites of enzymatic degradation of peptides and proteins in the small intestine.
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basement membrane, and the walls of lymph and blood
capillaries. Structure, composition, thickness, surface area,
and pH of this barrier are important considerations in drug
delivery systems.
Several mechanisms inhibit peptide access to the site of
action. By itself, the peptide cannot overcome the previous
barriers. Thus major efforts have been directed toward
reaching the target of effective and safe formulations for
peptide and protein drug carriers. Several strategies that
have been developed involve liposomes [15], emulsions
[16,17], microcapsules [13,18,19], and nanoparticles
[20,21]. Some authors have suggested that nanoparticles
may improve the bioavailability of peptide or protein
administered orally. Nanoparticles can actually protect these
labile drugs from the previous barriers and enhance their
absorption by optimizing their interaction with the absorp-
tion site in the gut wall or by directly transporting them
through the intestinal mucosa to systemic circulation [22].
Various mechanisms have been proposed to explain the
translocation of particulate material across the intestine: (1)
uptake via Peyer’s patches (PP) or isolated lymphoid
follicles [23-26], (2) intracellular uptake [26,27], and (3)
intercellular/paracellular passage [26,28]. Among these
three mechanisms, translocation via uptake in PP seems to
be a major pathway for rapid and substantial passage after
oral administration of nanoparticles [29]. Although possible
in some situations, passage of particles between the absorp-
tive cells is less likely if the barrier of tight junctions has not
been disrupted. Although there are numerous reports
showing evidence of absorption of particulate systems
by the GIT, the fate of nanoparticles after oral absorption
remains a controversial issue [30-32]. However, even
though there is a need for better quantification of particle
absorption as well as a more thorough understanding of the
variables affecting particle uptake, it must be concluded that
translocation of nanosized particles is possible. The question
remains whether the extent of particle translocation is com-
patible with a strategy of drug administration with thera-
peutic objectives [20].
Definition of nanoparticles
Nanoparticles are solid sub-micronic drug carriers of
natural, semisynthetic, or synthetic polymeric nature in the
nanometer size range [20,33]. Nanoparticles may or may not
be biodegradable and can be defined as solid colloidalparticles containing an active substance that are produced by
mechanical or chemical means. Nanoparticles are a collec-
tive name for nanospheres and nanocapsules as illustrated in
Figure 3. Nanospheres have a matrix-type structure. Drugs or
tracers may be absorbed at their surface, or entrapped or
dissolved within the particle. Nanocapsules are vesicular
systems in which the drug is confined to a cavity or inner
liquid core surrounded by a polymeric membrane [20]. In
this case the active substances are usually dissolved in the
inner core but may also be adsorbed at their surface [34].
Biomedical applications
Oral administration
Oral delivery, in which the therapeutic agent is absorbed
from the GIT, is the most desirable approach, but success
with peptides and proteins is limited by barriers to peptide
and protein absorption from the GIT. Nanoparticles can be
used to protect a labile drug from degradation in the GIT,
protect the GIT from drug toxicity, and deliver antigens to
the PP for oral immunization [35]. Briefly, nanoparticles
have been used as oral drug carriers for several reasons:
1. Improvement of the bioavailability of drugs with poor
absorption characteristics [36,37]
2. Prolongation of the residence time of drugs in
the intestine
3. High dispersion at the molecular level and conse-
quently increase of absorption
4. Delivery of vaccine antigens to gut-associated lym-
phoid tissue [23,24,38,39]
5. Control of the release of the drugs [40,41]
6. Targeting of therapeutic agents to a particular organ
and thus reducing toxicity [42]
7. Reduction of the GI mucosal irritation caused by
drugs [43,44]
8. Assurance of the stability of drugs in the GIT [45,46]
The next section describes examples of peptide and pro-
tein drugs that are being investigated for oral administration.
Insulin
Insulin is generally administered by injection in the
treatment of diabetes mellitus. However, insulin injected
subcutaneously seeps into the general circulation, thereby
exposing all tissues to an equal concentration and providing
the liver with only a fraction of the injected dose.Muscles and
Fig 3. Schematic representation of polymeric nanoparticles.
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hepatic monitoring of the insulin supply. The excessive
exposure of the vasculature and other smooth muscles to
injected insulin may trigger deleterious overstimulation of
growth, cell division, and other metabolic responses that form
the continuum of diabetic complications [47]. Thus injections
may cause local side effects and allergic reactions that may
lead to physical and mental pain. Oral administration has
been attempted for insulin delivery and multiple strategies
have been developed, such as coating insulin pellets with a
biodegradable azopolymer [48] that is degraded by bacteria in
the colon [25], emulsifying the insulin [49], or using drug
carriers such as liposomes [50] or nanoparticles [51-55].
First, polymer-free insulin nanoparticles were prepared
[54] forming 200 nm nanoparticles from a neutral insulin
solution by desolvation of the insulin followed by cross-
linking with glutaraldehyde [19]. Later, insulin was encap-
sulated into poly(isobutylcyanoacrylate) (PIBCA) nanopar-
ticles by interfacial polymerization [51,56]. Encapsulation
would protect the insulin against proteolytic enzymes and
promote absorption by the intestinal mucosa [57]. There is
evidence that nanoparticles may be able to pass from the gut
lumen to the blood compartment by means of a paracellular
pathway [28,58]. These insulin-containing nanocapsules
induced a significant hypoglycemic effect for several days
in fasting and fed diabetic rats but were ineffective in normal
rats [51]. This long duration of hypoglycemic effect was
attributed to a retarded passage [51] and progressive arrival of
intact nanoparticles containing the insulin through the gut
mucosa or postabsorptive steps [59]. Thus a slow process
of redistribution from that organ and/or a slow release of
insulin from nanocapsules could occur. Later studies showed
that insulin did not react with the alkylcyanoacrylate
monomer during nanocapsule formation and was located
within the oily core rather than adsorbed on the surface
[29,52], and the prolonged action could be due to the
retention of a portion of the colloidal system in the GIT.
Many polymers and methods have been investigated to
increase the bioavailability of oral insulin including insulin-
PIBCA nanospheres prepared by emulsion polymerization
[60,61]. Particles had a mean size of 150 nm. A lack of
protection against proteolytic enzymes was observed when
the spheres were suspended in water. However, when
dispersed in Mygliol (Dyna-France, France), the oily
medium conferred good protection against proteolysis.These observations indicate that, with the emulsion poly-
merization technique, hydrophilic peptides tend to diffuse
out to the surface of the formed particles, thus limiting their
protection.
As well, insulin microspheres coated with Eudragit L100
(Higuchi Co., Ltd., Tokyo, Japan) and containing a protease
inhibitor have been studied and found to provide effective
protection against degradation by pepsin [62]. Microspheres
containing insulin with aprotinin administered orally to
diabetic rats induced a significant and continuous hypogly-
cemic effect [18]. The same insulin microspheres without
protease inhibitor produced no marked hypoglycemic
response. Thus a strategy that utilizes a promoter of
absorption or protease inhibitor in association with micro-
particles or nanoparticles may be useful for enhancing the
efficacy of oral insulin formulations. Of course, repeated
administration of such a cocktail may cause damage to the
gastric mucosa and disturb the natural process of digesting
dietary proteins [20].
Insulin was also encapsulated in a blend of poly(fumaric
anhydride) (poly(FA) and poly(lactide-co-glycolide) (PLGA)
at a 50:50 ratio (poly(FA:PLGA)) using the inversion phase
method, leading to a mean particle size of 96.7 nm [63].
Animals fed the poly(FA:PLGA)-encapsulated insulin pre-
paration showed a better ability to regulate glucose load
than did the controls, suggesting that the insulin crossed the
intestinal barrier and was released from the microspheres in
a biologically active form [63].
Insulin has also recently been encapsulated in water-
containing nanocapsules [55], which when dispersed in a
biocompatible microemulsion, could facilitate intestinal
absorption, as demonstrated by a reduced blood glucose
level observed in diabetic rats [64].
Other techniques have been developed to encapsulate in-
sulin such as gas antisolvent [65], spray-drying [66], ionotro-
pic gelation [67], and dispersion polymerization technique
[68]. The new advances in nanotechnology applied to insulin
are focused on searching for safer, simpler, and scalablemeth-
ods by using naturally occurring polymers such as alginate.
Octreotide
Polyalkylcyanoacrylate (PACA) nanocapsules have been
used as biodegradable polymeric drug carriers for subcuta-
neous and oral delivery of octreotide, a long-acting soma-
tostatin analogue that has the ability to reduce secretion of
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is a naturally occurring tetrapeptide expressed by the hypo-
thalamus and GIT complex, exerting pluripotent biologic
actions. In addition to its central growth hormone release-
inhibiting effect, it depresses many endocrine and exocrine
secretions (insulin, glucagon, pancreatic polypeptide, pan-
creatic enzyme, and bicarbonate), responses to cholecysto-
kinin and secretin, and reduces GI motility and blood flow.
However, its short half-life necessitates administration by
intravenous infusion.
Octreotide, a synthetic octapeptide, has a long half-life
and many advantages over somatostatin. Administered
orally to estrogen-treated rats, octreotide-loaded nanocap-
sules improved (higher than 72%) the reduction of prolactin
secretion, increased plasma octreotide level, and also
improved and prolonged the therapeutic effect of a
somatostatin analogue given by the oral route [60].
Nanoparticles loaded with luteinizing hormone releasing
hormone (LHRH)
It is known that drug-polymer conjugates, such as labile
peptides coupled to hydroxypropylmethacrylamide or poly-
ethylene glycol, are effective formulations for enhancing
drug stability and improving targeting possibilities [19].
However, incorporating peptide into particles has proven to
be a more efficient way to protect the peptides against
proteolytic breakdown [19].
Both of these strategies were combined to synthesize a
novel drug-polymer conjugate that forms its own nano-
particulate delivery system, which was named the copoly-
merized peptide particle system [69,70]. Copolymeric
nanospheres were stable in vitro when incubated for 3 hours
in gut luminal contents, mucosal scrapings, fetal calf serum,
and rat serum [19]. LHRH-loaded copolymerized peptide
particle systems (mean size of 100 nm) were administered
orally, and encapsulant was measured by antibody radioim-
munoassay (RIA), showing a half-life of LHRH in blood of
2 to 8 minutes. The copolymerized peptide particle system
allowed peptide detection for a prolonged period of 12 hours,
whereas with the free peptide or with a LHRH-vinylacetate
derivative in buffer, no detectable absorption of LHRH was
observed. A maximum plasma uptake, amounting to 1.6% of
the administered dose, was detected 3 hours after single
dosing with the copolymerized peptide particle system.
Significant levels of LHRH were detected for as long as
12 hours. In multiple daily oral dosing this amount increased
in blood to 1.6 lg after the second day and after 5 days.
Although the fraction of the absorbed doses remained low,
these results were promising considering that the RIA may
have underestimated the extent of oral uptake of LHRH,
because of incomplete extraction of LHRH and also the
shielding effects of intact particles [19].
Calcitonin
Calcitonin is a peptide secreted by the parathyroid gland
of the human body. Calcitonin has a hypocalcemic actiondue to inhibition of bone resorption. It improves the
condition of bones by intensifying the subsidence of
osseous calcium and preventing its loss. The function of
calcitonin is to land hematic calcium onto the bones and
convert it into osseous calcium, by which bones will be
strengthened. Calcitonin has been used for treating Paget’s
disease (osteitis deformans), hypercalcemia caused by
neoplastic diseases, vitamin D intoxication, and hyperpara-
thyroidism by subcutaneous or intramuscular administra-
tion. The absorption of calcitonin by the nasal route remains
poor and highly variable [71]. Therefore, preparing a potent
oral formulation with this peptide would provide a valuable
alternative [72].
Calcitonin has been encapsulated into polyacrylamide
nanospheres [73], PIBCA nanocapsules [73], and chitosan
nanoparticles[74]. Salmon calcitonin was also encapsulated
into polystyrene nanoparticles composed of graft copoly-
mers with a hydrophobic backbone and hydrophilic
branches, prepared by the dispersion copolymerization of
hydrophilic polyvinyl macromonomers with styrene in a
polar solvent [75]. When administered orally to rats, the
decrease in blood concentration of ionized calcium was
considerably greater than after oral administration of
calcitonin in water. The absorption enhancement of calci-
tonin by these nanoparticles probably results from both
bioadhesion to the GI mucosa and the increase of the
stability of calcitonin in the GIT.
Cyclosporine A
Cyclosporine is a cyclic nonribosomal peptide produced
by the fungus Hypocladium inflatum gams, initially isolated
from a Norwegian soil sample. Apart from its use in
transplant medicine because of its immunosuppressive
properties, cyclosporine is also used in treatment of
psoriasis and infrequently of rheumatoid arthritis and related
diseases, although it is used only in severe cases. More
recently, cyclosporine has begun to be used as an aid in
treating patients suffering from ulcerative colitis with
positive results. After oral administration this compound is
absorbed only incompletely and variably, leading to a
relative bioavailability of less than 50% [72]. In contrast
to most peptides, it is particularly lipophilic. It is practically
insoluble in water and is soluble in alcohol. These
characteristics are favorable for encapsulation in particles.
Several polymers have been used including poly(isohex-
ylcyanoacrylate) (PIHCA) and poly(q-caprolactone) (PCL)
[76]. Cyclosporine was encapsulated in PIHCA by interfa-
cial and emulsion polymerization [72]. The nanoparticle
formulation had a notably increased bioavailability com-
pared with that of the commercial formulation.
Anticancer drugs
Significant advances have already taken place in the
treatment of some malignancies; however, there has been
little progress in the treatment of most common solid tumors
such as those of the breast, lung, colorectum, and brain. To
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to the tumor cells, which is far from being the case
everywhere within the tumor. The special structure and
location of solid tumors such as the blood-brain barrier is
also considered an obstacle for many drugs, such as
antibiotics, antineoplastic agents, and a variety of drugs
active in the central nervous system, especially neuro-
peptides [29]. In addition to such a constitutive resistance to
treatments as a result of physiologic considerations, the
emergence of multidrug resistance is often an additional
problem to be solved, including overexpression of the
transmembrane glycoprotein Pgp (efflux with PgP pump),
multidrug resistance protein, and glutathione S-transferase
or topoisomerase modifications [77]. Because of this
situation higher doses of anticancer drugs must be given.
However, toxicity places limitations on therapy with
most chemotherapeutic agents, including cardiotoxicity
and myelosuppression [78].
Consequently, there is a need for a new method of
administration that could concentrate the drug close to the
tumor site, avoiding widespread distribution. Because drug
targeting can modulate drug distribution, the use of nano-
particle carriers has been proposed to have potential for
increasing the efficacy of chemotherapy while reducing
adverse effects. Nanoparticles show a tendency for accumu-
lation in certain tumors [79-81] for several possible reasons:
various tumors show enhanced endocytotic activity; nano-
particles may easily escape through leaky endothelial tissue
in the tumor; and finally, nanoparticles may be adsorbed on
the surface of blood vessels in the tumor due to an enhanced
bioadhesiveness for these particles of blood vessel walls in
the tumor. Curiously, some studies have demonstrated that
nanoparticles can overcome the blood-brain barrier to deliver
drugs to the brain [82,83]. An example of this ability to
overcome the blood-brain barrier is dalargin, a peptide that
shows good stability in the bloodstream. Normally the
topical injection of this peptide induces analgesia, whereas
the systemic administration of this peptide shows no effect
on central analgesic mechanisms [84]. This peptide was
nanoencapsulated in poly(butylcyanoacrylate) with polysor-
bate 85 coating (Science Lab, Texas). The antinociceptive
effect obtained with dalargin by this delivery route was
not as pronounced though rather prolonged [82]. In the
literature concerning tumor therapy, two major types of
particle carriers are most frequently encountered: PACA and
poly(lactic acid) nanoparticles.
Vaccines
The GIT is constantly invaded by potentially harmful
antigens, which are usually destroyed by the mucosal barrier
via a combination of nonimmunologic barriers such as
gastric acidity, proteolytic enzymes, peristalsis, commensal
microflora, and mucus, as well as the immunologic barrier
[85,86]. The immune response is stimulated when antigens
gain access to lymphoid tissue within the GIT. The gut-
associated lymphoid tissue is distributed into four anatomicregions [87]: the lamina propria, which contains large
numbers of plasma cells as well as macrophages, neutro-
phils, eosinophilis, and mast cells; the intraepithelial
lymphocytes, which are dispersed between the epithelial
cells of the mucosal membrane; isolated lymphoid follicles,
present throughout the intestine and colon; PP, which are
clusters of lymphoid follicles along the wall of the small
intestine [88]. Lymphoid tissue of the lamina propria and
intraepithelial lymphocytes are collectively known as the
diffuse lymphoid tissue. An immune response is elicited
through lymphoid tissue of the PP and isolated lymphoid
follicles [88].
Thus far oral immunization has been accomplished by
either the use of live attenuated organisms or the use of
peptides, which have the capacity to bind and be absorbed at
the intestinal level and to generate both a local mucosal
response and, if necessary, a systemic immune response
[88]. A third method of oral immunization based on DNA
vaccines that has recently been developed is gaining ever
more attention. DNA vaccines elicit immune responses by
expressing proteins in vaccinated hosts. The DNA vaccines
are simple rings of DNA containing a gene encoding an
antigen, and a promoter/terminator to cause expression of
the gene in mammalian cells [89]. This may constitute a
future approach for the administration of antigenic peptides.
Oral vaccination may fail for several reasons, including:
failure to swallow the vaccine, inactivation by gastric acid
and intestinal enzymes, poor bioavailability, interference
from other bacteria and viruses in the GIT, mutual
interference if more than one type of live vaccine is
administered concurrently, and excessively rapid transit of
the vaccine through the intestine limiting its binding to
mucosal cell receptors and hence stimulation of an adequate
immune response. To overcome the need for higher and
more frequent dosing required by oral administration and to
minimize vaccine failure, researchers have attempted several
strategies including particulate drug delivery systems and
subsequent delivery mainly through the M cells of the PP.
The use of particulate carrier systems for oral delivery of
antigens might be expected to confer several advantages
over alternative approaches, including: promotion by
particles of uptake by the PP; protection against antigen
degradation; the possibility of delivering several antigens
simultaneously; the added ability to incorporate immuno-
logic adjuvants; avoidance of immunity to the carrier, thus
permitting frequent boosting; the capacity for controlled or
bpulsedQ release of antigen; the potential possibility of
directing the carrier to the uptake site by adding a specific
targeting moiety to promote the efficiency of delivery [87].
It was first suggested more than 30 years ago that the
soluble or particulate nature of an antigen could affect the
response to its oral administration [90]. Subsequently it was
demonstrated that the association of a soluble antigen with a
particulate carrier (polyacrylamide microparticles, 1–3 lm)
before oral administration led to the induction of an
enhanced secretory immune response [91], which was
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gain access to the PP. However, the only immune response
measured was that elicited by a hapten conjugated to a
carrier protein, whereas responses to the carrier protein were
not determined [91]. Later work [92] demonstrated that
latex particles with a protein coating were taken up into the
PP, again highlighting the potential of particulate carriers as
antigen delivery systems for oral immunization [92].
The first applications of nanoparticles were as adjuvants
for vaccines [93,94]. Viruses, virus subunits, bacterial
toxoids, peptides, and other antigens have been incorporated
in or adsorbed by nanoparticles [95,96]. Many polymers
have been applied such as poly(methylmethacrylate) [94],
poly(d,l-lactide-co-glycolide) [24], and polystyrene nano-
particles [38,39,97], representing efficient and possibly safe
carriers for vaccines. It was interesting to note that the
amount of uptake by the PP was dependent on size. The
critical size of the particles taken up by the PP in these
studies varied, but this difference may be due to physico-
chemical differences in the administered particles, or to the
experimental design or method of analysis of particulate
uptake. However, all studies demonstrated numerous
advantages to nanoparticles over larger particles.
Coupled with advances in molecular biology, virology,
immunology, and controlled delivery, nanoparticulate sys-
tems may be the next generation of effective vaccines in the
field of oral immunization [22].
Parenteral administration
Potential applications of colloidal drug carriers adminis-
tered intravenously can be summarized in terms of the
concentration of drugs in accessible sites, the rerouting of
drugs away from sites of toxicity, and increasing the
circulation half-life of labile or rapidly eliminated drugs
such as peptides and proteins. Because colloidal drug
carriers are naturally concentrated within macrophages, they
are well suited as drug carriers to these particular cells. The
use of peptides and polypeptides for human and animal
treatment is problematic, because the tendency of some of
these drugs to be rapidly degraded by proteolytic enzymes
in the GIT and not to be absorbed through the intestinal wall
means they are generally ineffective by the oral route; thus
they have generally been administered by parenteral routes.
Anticancer drugs
As described above, drug targeting can modulate drug
distribution, and colloidal carriers have shown promise for
increasing the efficacy of chemotherapy while reducing
adverse effects. One of the most promising applications of
nanoparticles is their use as carriers for anticancer agents.
Immunotherapy with macrophage activators has been
suggested as an alternative to conventional therapy for
treating metastatic tumors. Among these, muramyldipeptide
(MDP) has promising properties in vitro but because of its
hydrophilicity is cleared too rapidly to produce an anti-
metastatic effect in vivo [19]. MDP is a low-molecular-weight, soluble synthetic compound derived from the
peptidoglycan of mycobacteria and is used as a macrophage
activator that interacts with intracellular receptors. MDP
penetrates poorly into macrophages and is eliminated
rapidly after intravenous administration. These problems
can be overcome by encapsulation within nanoparticles
[98,99]. A lipophilic derivative of this substance, the
muramyltripeptide-cholesterol (MTP-chol), was prepared
[98] and successfully encapsulated in isobutylcyanoacrylate
nanocapsules by an interfacial polymerization. The encap-
sulation of the MTP-chol into nanoparticles leads to a
stimulation of the antimicrobial and anticancer activity of
macrophages. As well, an antiangiogenesis peptide, argi-
nine-rich hexapeptide, was encapsulated into chitosan-
dextran sulfate nanoparticles [100] to achieve sustained
release with the intention of prolonging biologic activity of
the peptide. It was suggested that this peptide may be
effective for the treatment of various human tumors and
other angiogenesis-dependent diseases that are related to the
action of vascular endothelial growth factor. These hydro-
philic nanoparticles were prepared by a coacervation
process under extremely mild conditions with ionic cross-
linkage, without involving high temperatures or sonication,
and may have potential as a carrier for small peptides.
Hormones
Human growth hormone–releasing factor (hGRF) is a
hormone released from the arcuate nucleus of the hypothal-
amus that stimulates the release of growth hormone. The
effects of growth hormone on the tissues of the body can
generally be described as anabolic (building up). hGRF is
used in the treatment of several diseases such as Turner’s
syndrome and Prader-Willi syndrome. However, frequent
injections are required to produce an effective therapy. An
alternative for reducing the drawbacks of parenteral
administration of this peptide is to develop long-acting
parenteral preparations. This approach, however, is compli-
cated by the physicochemical characteristics of peptide
[101]. Gautier et al. developed a nanoparticulate system
with hGRF. In fact, PIHCA nanoparticles [101] were able to
protect against enzymatic degradation and to deliver hGRF
after subcutaneous administration.
Other drugs
Nanoparticles have been proposed as an intramuscular
formulation for sustained release of testosterone [102] and
for subcutaneous treatment of diabetes mellitus with insulin-
PIBCA nanospheres [36] and nanocapsules [51].
Ophthalmic application
Nanoparticles have shown promising results over the last
10 years in ophthalmology, providing protection of drug from
chemical and enzymatic degradation, improved tolerance, in-
creased corneal uptake, and longer intraocular half-life [103].
The first report on particulate systems for ocular delivery
was in 1980 by Gurny and Taylor [104]. Subsequently,
Table 1
Some biomedical applications of polymeric nanoparticles adapted from
Murillo [126].
Biomedical applications Drugs
Chemotherapy Calcitonin [73]
Dalargin [82-84]
MTP-chol [98]
Progesterone [110]
Cyclosporine [127]
Doxorubicin [127]
Endothelial vascular growth factor [128]
Immunoprophylaxis Glycoproteins [129]
HER 2-expressing murine sarcomas [130]
HIV-1MN gp 120 [96]
Antiinflammatory Cyclosporine [72,76]
Bioadhesion Insulin [67]
Calcitonin [75]
Poorly water-soluble drugs [131]
Diagnostic Contrast agents and other molecules
[132-134]
Gene therapy DNA [135]
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advantage of prolonged residence time, because the short
elimination half-life of ophthalmologic drugs remains a
major problem in ocular therapy [20]. Cyclosporine A was
also nanoencapsulated in three important studies involving
PCL [105], PACA [106,107], and chitosan [108] to evaluate
aqueous suspensions of cyclosporine A–loaded nanopar-
ticles [103]. The nanoparticle approach is not yet completely
satisfactory, because the precorneal clearance is still too
rapid. Of the three cyclosporine A carriers the most
promising is chitosan because of the therapeutic levels
achieved in periocular tissues and its good tolerance [103];
consequently it has been widely used in ocular drug
formulations [109].
Pharmacologic efficiency may be influenced not only by
the nature of the carrier but also by the physicochemical
presentation of the drug. Progesterone was also associated
with nanoparticles but in this case was less efficient than the
administration of a simple aqueous solution [110]. This
result was attributed to a high affinity of progesterone for the
nanoparticles, which made the drug less available for
corneal absorption. Nevertheless, it was found that the
concentration of 14C-labeled PACA nanoparticles in the
cornea, conjunctiva, nictitating membrane, and aqueous
humor was three to five times higher in eyes in which a
chronic inflammation had been induced [111]. This obser-
vation suggests that these nanoparticles have enhanced
bioadhesiveness on inflamed tissues. It was demonstrated
that nanoparticles adhere to inflamed ocular tissue at a level
that is four times higher than in healthy tissue. These
particles also hold promise for the targeting of anti-
inflammatory drugs to inflamed eyes [112].
Pulmonary administration
In contrast to intravenous or oral application, pulmonary
application via inhalation is accompanied by several uniquechallenges [113], the first of which is the atomization of the
drug formulation in a form suitable for inhalation. It is
generally accepted that aerosol particles of 1 to 5 lm are
required for deposition in the alveolar region of the lung,
which can be classified as the region of the highest systemic
absorption. The primary influences on aerosol particle size
and, ultimately, the site of aerosol deposition, include the
design of the inhalation device as well as the physicochem-
ical properties of the drug formulation [114].
Among the various drug delivery systems considered for
pulmonary application, biodegradable polymeric nanopar-
ticles demonstrate potential advantages to administration of
peptidic and protein drugs such as insulin [115]. In
comparison to liposomal formulations, polymeric nano-
particles may show a greater stability to the extreme forces
generated during the nebulization process, thus eliminating
the possibility of drug leakage [116,117]. An additional
advantage of nanoparticle formulations is that particles with
a diameter less than 1 lm are more easily incorporated in the
brespirable percentageQ of aerosolized droplets [114].
In addition to the size of the individual particles, concen-
trations as well as surface characteristics play an important
role in determining the physicochemical properties of the
suspension, and subsequently, its behavior during nebuliza-
tion [114]. Thus pulmonary application via inhalation
presents unique challenges but also promising perspectives
in nanoparticulate drug delivery systems.
Other routes
Colloidal drug carrier systems have been used to
concentrate g-interferon in the skin for the treatment of
cutaneous herpes. Cytokine accumulates in the stratum
corneum, rather than remaining on the surface as occurs
after administration of a simple solution [118]. Other drugs
such as minoxidil have been successfully encapsulated and
administered by the transdermal route [119]. With regard to
the nasal route, the nasal mucosa’s high permeability affords
easy access of drug to the absorption site. Nanoparticles
loaded with drugs such as insulin [120,121], DNA [122],
and tetanus toxoid [123] have been encapsulated and
administered by this route.
These results are important, and the research on nano-
technology is consequently gaining momentum. An example
of the success of nanotechnology is the recent entry of
cyanoacrylate nanoparticles into Phase II clinical trials
for use in the treatment of resistant cancers. Nevertheless,
several issues remain to be resolved.
Finally, examples of biomedical applications of nano-
particles and various examples of drugs are summarized
in Table 1.
Conclusions
Nanoparticles are particularly useful for formulating new
drugs because they can provide protection from degradation
in biologic fluids and promote penetration into cells. As
C. Pinto Reis et al. / Nanomedicine: Nanotechnology, Biology, and Medicine 2 (2006) 53–6562shown in this review, there is a great deal of interest in the
properties of nanoparticles and their potential applications.
Nanoparticles, because of their sustained-release properties,
subcellular size, and biocompatibility with tissue and
cells, seem to hold promise for the achievement of these
important objectives [124]. Nanoparticles permit alterations
in the bioavailability of drugs and improve the pharmaco-
kinetic profile of numerous drugs with biomedical purposes.
Finally, if nanoparticulate systems show great promise as
a tool for the development of peptide and protein
administration, their final success will depend heavily on
the will of the pharmaceutical industry to develop new
polymers, test their potential in therapeutics, and demon-
strate their safety. Nanoparticulate systems able to improve
the efficacy of both established drugs and new molecules
will likely be available in the near future.References
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